NOT FOR DISTRIBUTION
Header cover image

Market Cap

€185.1m

Last Updated

2021/05/07 20:47 UTC

Data Sources

Company Financials +

Executive Summary

Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. More Details


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has Poxel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: POXEL is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: POXEL's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-3.1%

POXEL

-4.9%

FR Biotechs

1.1%

FR Market


1 Year Return

-24.3%

POXEL

29.9%

FR Biotechs

42.2%

FR Market

Return vs Industry: POXEL underperformed the French Biotechs industry which returned 29% over the past year.

Return vs Market: POXEL underperformed the French Market which returned 42.8% over the past year.


Shareholder returns

POXELIndustryMarket
7 Day-3.1%-4.9%1.1%
30 Day-4.0%-3.9%4.3%
90 Day-6.9%-16.8%12.0%
1 Year-24.3%-24.3%29.9%29.9%45.5%42.2%
3 Year-10.2%-10.2%-17.8%-17.8%28.5%18.2%
5 Year-39.1%-39.1%-47.0%-47.1%86.4%59.8%

Long-Term Price Volatility Vs. Market

How volatile is Poxel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Poxel undervalued compared to its fair value and its price relative to the market?

6.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate POXEL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate POXEL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: POXEL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: POXEL is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate POXEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: POXEL is overvalued based on its PB Ratio (6.9x) compared to the FR Biotechs industry average (4.5x).


Future Growth

How is Poxel forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

1.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: POXEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: POXEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: POXEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: POXEL's revenue (22.9% per year) is forecast to grow faster than the French market (6.8% per year).

High Growth Revenue: POXEL's revenue (22.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if POXEL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Poxel performed over the past 5 years?

-8.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: POXEL is currently unprofitable.

Growing Profit Margin: POXEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: POXEL is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.

Accelerating Growth: Unable to compare POXEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POXEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (18.9%).


Return on Equity

High ROE: POXEL has a negative Return on Equity (-118.52%), as it is currently unprofitable.


Financial Health

How is Poxel's financial position?


Financial Position Analysis

Short Term Liabilities: POXEL's short term assets (€46.0M) exceed its short term liabilities (€16.5M).

Long Term Liabilities: POXEL's short term assets (€46.0M) exceed its long term liabilities (€21.7M).


Debt to Equity History and Analysis

Debt Level: POXEL's debt to equity ratio (84.2%) is considered high.

Reducing Debt: POXEL's debt to equity ratio has increased from 10.4% to 84.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: POXEL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if POXEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Poxel current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate POXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate POXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if POXEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if POXEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of POXEL's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Thomas Kuhn

12.33yrs

Tenure

€443,073

Compensation

Mr. Thomas Kuhn, PharmD, MBA co-founded Poxel SA in 2009 and serves as its Chief Executive Officer and its Director since June 23, 2010. Mr. Kuhn joined Merck Serono in 2000, where he held various position...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD534.14K) is about average for companies of similar size in the French market ($USD467.32K).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: POXEL's management team is seasoned and experienced (6 years average tenure).


Board Members

Experienced Board: POXEL's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.


Top Shareholders

Company Information

Poxel S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Poxel S.A.
  • Ticker: POXEL
  • Exchange: ENXTPA
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €185.131m
  • Shares outstanding: 28.57m
  • Website: https://www.poxelpharma.com

Number of Employees


Location

  • Poxel S.A.
  • Immeuble Le Sunway
  • 259-261 Avenue Jean Jaurès
  • Lyon
  • Rhône-Alpes
  • 69007
  • France

Listings


Biography

Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 20:47
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.